Cargando…

Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells

Exopolysaccharide (EPS) is a bacterial extracellular carbohydrate moiety which has been associated with immunomodulatory activity and host protective effects of several gut commensal bacteria. Bifidobacterium breve are early colonizers of the human gastrointestinal tract (GIT) but the role of EPS in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hickey, Ana, Stamou, Panagiota, Udayan, Sreeram, Ramón-Vázquez, Ana, Esteban-Torres, Maria, Bottacini, Francesca, Woznicki, Jerzy Adam, Hughes, Owen, Melgar, Silvia, Ventura, Marco, Van Sinderen, Douwe, Rossini, Valerio, Nally, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242212/
https://www.ncbi.nlm.nih.gov/pubmed/34220742
http://dx.doi.org/10.3389/fmicb.2021.653587
_version_ 1783715584229244928
author Hickey, Ana
Stamou, Panagiota
Udayan, Sreeram
Ramón-Vázquez, Ana
Esteban-Torres, Maria
Bottacini, Francesca
Woznicki, Jerzy Adam
Hughes, Owen
Melgar, Silvia
Ventura, Marco
Van Sinderen, Douwe
Rossini, Valerio
Nally, Ken
author_facet Hickey, Ana
Stamou, Panagiota
Udayan, Sreeram
Ramón-Vázquez, Ana
Esteban-Torres, Maria
Bottacini, Francesca
Woznicki, Jerzy Adam
Hughes, Owen
Melgar, Silvia
Ventura, Marco
Van Sinderen, Douwe
Rossini, Valerio
Nally, Ken
author_sort Hickey, Ana
collection PubMed
description Exopolysaccharide (EPS) is a bacterial extracellular carbohydrate moiety which has been associated with immunomodulatory activity and host protective effects of several gut commensal bacteria. Bifidobacterium breve are early colonizers of the human gastrointestinal tract (GIT) but the role of EPS in mediating their effects on the host has not been investigated for many strains. Here, we characterized EPS production by a panel of human B. breve isolates and investigated the effect of EPS status on host immune responses using human and murine cell culture-based assay systems. We report that B. breve EPS production is heterogenous across strains and that immune responses in human THP-1 monocytes are strain-specific, but not EPS status-specific. Using wild type and isogenic EPS deficient mutants of B. breve strains UCC2003 and JCM7017 we show that EPS had strain-specific divergent effects on cytokine responses from murine bone marrow derived macrophages (BMDMs) and dendritic cells (BMDCs). The B. breve UCC2003 EPS negative (EPS(–)) strain increased expression of cytokine genes (Tnfa, Il6, Il12a, and Il23a) relative to untreated BMDCs and BMDCs treated with wild type strain. B. breve UCC2003 and JCM7017 EPS(–) strains increased expression of dendritic cell (DC) activation and maturation marker genes (Cd80, Cd83, and Cd86) relative to untreated BMDCs. Consistent with this, BMDCs co-cultured with B. breve UCC2003 and JCM7017 EPS(–) strains engineered to express OVA antigen activated OVA-specific OT-II CD4(+) T-cells in a co-culture antigen-presentation assay while EPS proficient strains did not. Collectively, these data indicate that B. breve EPS proficient strains use EPS to prevent maturation of DCs and activation of antigen specific CD4(+) T cells responses to B. breve. This study identifies a new immunomodulatory role for B. breve EPS and suggests it may be important for immune evasion of adaptive immunity by B. breve and contribute to host-microbe mutualism.
format Online
Article
Text
id pubmed-8242212
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82422122021-07-01 Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells Hickey, Ana Stamou, Panagiota Udayan, Sreeram Ramón-Vázquez, Ana Esteban-Torres, Maria Bottacini, Francesca Woznicki, Jerzy Adam Hughes, Owen Melgar, Silvia Ventura, Marco Van Sinderen, Douwe Rossini, Valerio Nally, Ken Front Microbiol Microbiology Exopolysaccharide (EPS) is a bacterial extracellular carbohydrate moiety which has been associated with immunomodulatory activity and host protective effects of several gut commensal bacteria. Bifidobacterium breve are early colonizers of the human gastrointestinal tract (GIT) but the role of EPS in mediating their effects on the host has not been investigated for many strains. Here, we characterized EPS production by a panel of human B. breve isolates and investigated the effect of EPS status on host immune responses using human and murine cell culture-based assay systems. We report that B. breve EPS production is heterogenous across strains and that immune responses in human THP-1 monocytes are strain-specific, but not EPS status-specific. Using wild type and isogenic EPS deficient mutants of B. breve strains UCC2003 and JCM7017 we show that EPS had strain-specific divergent effects on cytokine responses from murine bone marrow derived macrophages (BMDMs) and dendritic cells (BMDCs). The B. breve UCC2003 EPS negative (EPS(–)) strain increased expression of cytokine genes (Tnfa, Il6, Il12a, and Il23a) relative to untreated BMDCs and BMDCs treated with wild type strain. B. breve UCC2003 and JCM7017 EPS(–) strains increased expression of dendritic cell (DC) activation and maturation marker genes (Cd80, Cd83, and Cd86) relative to untreated BMDCs. Consistent with this, BMDCs co-cultured with B. breve UCC2003 and JCM7017 EPS(–) strains engineered to express OVA antigen activated OVA-specific OT-II CD4(+) T-cells in a co-culture antigen-presentation assay while EPS proficient strains did not. Collectively, these data indicate that B. breve EPS proficient strains use EPS to prevent maturation of DCs and activation of antigen specific CD4(+) T cells responses to B. breve. This study identifies a new immunomodulatory role for B. breve EPS and suggests it may be important for immune evasion of adaptive immunity by B. breve and contribute to host-microbe mutualism. Frontiers Media S.A. 2021-06-16 /pmc/articles/PMC8242212/ /pubmed/34220742 http://dx.doi.org/10.3389/fmicb.2021.653587 Text en Copyright © 2021 Hickey, Stamou, Udayan, Ramón-Vázquez, Esteban-Torres, Bottacini, Woznicki, Hughes, Melgar, Ventura, Van Sinderen, Rossini and Nally. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Hickey, Ana
Stamou, Panagiota
Udayan, Sreeram
Ramón-Vázquez, Ana
Esteban-Torres, Maria
Bottacini, Francesca
Woznicki, Jerzy Adam
Hughes, Owen
Melgar, Silvia
Ventura, Marco
Van Sinderen, Douwe
Rossini, Valerio
Nally, Ken
Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells
title Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells
title_full Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells
title_fullStr Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells
title_full_unstemmed Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells
title_short Bifidobacterium breve Exopolysaccharide Blocks Dendritic Cell Maturation and Activation of CD4(+) T Cells
title_sort bifidobacterium breve exopolysaccharide blocks dendritic cell maturation and activation of cd4(+) t cells
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242212/
https://www.ncbi.nlm.nih.gov/pubmed/34220742
http://dx.doi.org/10.3389/fmicb.2021.653587
work_keys_str_mv AT hickeyana bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT stamoupanagiota bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT udayansreeram bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT ramonvazquezana bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT estebantorresmaria bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT bottacinifrancesca bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT woznickijerzyadam bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT hughesowen bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT melgarsilvia bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT venturamarco bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT vansinderendouwe bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT rossinivalerio bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells
AT nallyken bifidobacteriumbreveexopolysaccharideblocksdendriticcellmaturationandactivationofcd4tcells